You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations.
Click “OK” to confirm you are a Healthcare Professional.
Imagine fewer trips to the bathroom. Fewer accidents. And resuming the relationships and activities you love.
Evidence suggests that breakdowns in the bladder-brain communication pathway are the root cause of OAB and non-obstructive urinary retention.1-3 While other therapies focus on the bladder muscles, neuromodulation therapies target the nerves, which is thought to help restore normal bladder function.*
EXPLORE BLADDER CONTROL THERAPIES:
THE RELIEF YOU'VE BEEN WAITING FOR
Implanting a neurostimulator has risks similar to any surgical procedure, including swelling, bruising, bleeding, and infection. Talk with your doctor about ways to minimize these risks.
The most common adverse events experienced during clinical studies included pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms.
You may be a good candidate for Bladder Control Therapy delivered by sacral neuromodulation if:
Unlike other bladder control treatments, sacral neuromodulation therapy lets you try it first. It’s called an evaluation — like a test run, not a long-term commitment.
Complications can occur with the evaluation, including movement of the wire, technical problems with the device, and some temporary pain. Your doctor or nurse will show you how to use the system, and inform you of any activity restrictions and other precautions related to the evaluation.
REGAIN YOUR FREEDOM
PTNM only treats the symptoms of OAB, not urinary retention.
Improves quality of life8 which may include going to the bathroom less often and getting back to activities you enjoy.
Most common side effects of PTNM are temporary and include mild pain or skin inflammation at or near the stimulation site.
Success with SNM is defined as a 50% or greater reduction in your troublesome bladder symptoms.
These patient groups were analyzed based on the treatment they were assigned: incomplete data was counted as ”failures.” Another analysis reported 61% of people achieved success with SNM, compared to 42% who used medications.
Restored bladder function is defined as a measurable reduction in urinary frequency and/or urinary incontinence episodes following PTNM treatment.
Dasgupta R. Critchley HD, Dolan RJ, Fowler CJ. Changes in brain activity following sacral Neuromodulation for urinary retention. J Urol. 2005;174:2268-2272
Griffiths D, Derbyshire S, Stenger A, Resnick N. Brain control of normal and overactive bladder. J Urol. 2005;174:1862-1867.
Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn. 2008;27(6):466-474.
Noblett K, Siegel S, Mangel J, et al. Results of a Prospective, Multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn. 2014. doi:10.1002/nau.22707.
Foster RT Sr, Anoia EJ, Webster GD, Amundsen CL. In patients undergoing neuromodulation for intractable urge incontinence a reduction in 24-hr pad weight after the initial test stimulation best predicts long-term patient satisfaction. Neurourol Urodyn. 2007;26:213-217.
Visco A, Brubaker L, Richter HE et al. Anticholinergic Therapy vs. OnabotulinumtoxinA for Urgency Urinary Incontinence. New Engl J Med. 2012;367(19):1803-1813.
Peters KM, MacDiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055-1061.
Peters KM, Carrico DJ, et al. “Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial.” J Urol. 2010;183(4): 1438-1443.
Peters, K.M., D.J. Carrico, et al. (2013). “Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.” J Urol. 189(6) 2194-2201.8.